Elizabeth A Misener

Synthesis and evaluation of aminomethyl dihydrocinnamates as a new class of PPAR ligands.

A. R. Miller, J. Brozinick, C. Montrose‐Rafizadeh, 2006, Bioorganic & medicinal chemistry letters.

Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.

R. Campbell, P. Iversen, M. Clay, 2004, Journal of medicinal chemistry.

The development of potent and selective bisarylmaleimide GSK3 inhibitors.

R. Campbell, B. Anderson, T. Engler, 2005, Bioorganic & medicinal chemistry letters.

A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.

K. Ogilvie, J. Brozinick, G. Etgen, 2002, Diabetes.

2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents.

J. Brozinick, C. Montrose‐Rafizadeh, C. Lamas, 2005, Bioorganic & medicinal chemistry letters.

Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.

V. Devanarayan, J. Brozinick, C. Montrose‐Rafizadeh, 2006, Bioorganic & medicinal chemistry letters.